The Coronavirus disease 2019 (COVID-19) pandemic is expected to have a long-lasting impact on the approach to care for patients at risk for and with hepatocellular carcinoma (HCC) due to the risks from potential exposure and resource reallocation. The goal of this document is to provide recommendations on HCC surveillance and monitoring, including strategies to limit unnecessary exposure while continuing to provide high-quality care for patients. Publications and guidelines pertaining to the management of HCC during COVID-19 were reviewed for recommendations related to surveillance and monitoring practices, and any available guidance was referenced to support the authors’ recommendations when applicable. Existing HCC risk stratification models should be utilized to prioritize imaging resources to those patients at highest risk of incident HCC and recurrence following therapy though surveillance can likely continue as before in settings where COVID-19 prevalence is low and adequate protections are in place. Waitlisted patients who will benefit from urgent LT should be prioritized for surveillance whereas it would be reasonable to extend surveillance interval by a short period in HCC patients with lower risk tumor features and those more than 2 years since their last treatment. For patients eligible for systemic therapy, the treatment regimen should be dictated by the risk of COVID-19 associated with route of administration, monitoring and treatment of adverse events, within the context of relative treatment efficacy.

由于潜在暴露和资源重新分配的风险，预计 2019 年冠状病毒病 (COVID-19) 大流行将对治疗有肝细胞癌 (HCC) 风险和患有肝细胞癌 (HCC) 的患者的方法产生长期影响。本文件的目的是提供有关 HCC 监测和监测的建议，包括在继续为患者提供高质量护理的同时限制不必要暴露的策略。审查了与 COVID-19 期间 HCC 管理相关的出版物和指南，以获得与监测和监测实践相关的建议，并参考了任何可用指南以支持作者的建议（如适用）。应利用现有的 HCC 风险分层模型，将影像资源优先用于那些发生 HCC 和治疗后复发风险最高的患者，尽管在 COVID-19 流行率低且保护措施到位的环境中，监测可能会像以前一样继续进行。将从紧急 LT 中获益的候补患者应优先进行监测，而对于具有较低风险肿瘤特征和距离上次治疗超过 2 年的 HCC 患者，短期延长监测间隔是合理的。对于符合全身治疗条件的患者，治疗方案应根据与给药途径、监测和不良事件治疗相关的 COVID-19 风险，在相对治疗效果的背景下确定。